Skip NavigationSkip to Content
Return Return to Search Results

A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model

  1. Author:
    Lim, Hye In
    Yamamoto, Jun
    Inubushi, Sachiko
    Nishino, Hiroto
    Tashiro, Yoshihiko
    Sugisawa, Norihiko
    Han, Quinhong
    Sun, Y U
    Choi, Hee Jun
    Nam, Seok Jin
    Kim, Moon Bo
    Lee, Ji Sun
    Hozumi, Chihiro
    Bouvet, Michael
    Singh,Shree Ram
    Hoffman, Robert M

  2. Author Address

    AntiCancer Inc, San Diego, CA, U.S.A., Department of Surgery, University of California, San Diego, CA, U.S.A., Department of Surgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea., Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., MetaBio, Inc., Seoul, Republic of Korea., AntiCancer Japan Inc, Narita, Japan., Basic Research Laboratory, National Cancer Institute, Frederick, MD, U.S.A. all@anticancer.com singhshr@mail.nih.gov., AntiCancer Inc, San Diego, CA, U.S.A. all@anticancer.com singhshr@mail.nih.gov.,
    1. Year: 2020
    2. Date: May
  2. Journal: Anticancer research
    1. 40
    2. 5
    3. Pages: 2481-2485
  4. Type of Article: Article
  1. Abstract:

    In the present study, the breast cancer patient-derived orthotopic xenograft (PDOX) model was used to identify an effective drug for a highly aggressive triple negative breast cancer (TNBC). The TNBC tumor from a patient was implanted in the right 4th inguinal mammary fat pad of nude mice to establish a PDOX model. Three weeks later, 19 mice were randomized into the untreated-control group (n=10) and the eribulin treatment group (n=9, eribulin, 0.3 mg/kg, i.p., day 1). On day 8, eribulin significantly inhibited tumor volume compared to the control group (p< 0.01). Eribulin regressed tumors in 3 mice (33.3%) and apparently eradicated them in 6 mice (66.7%). At day 14, tumor regrowth was observed in 2 mice of the eribulin group, which was undetectable on day 8. However, 44.4% (4 out of 9) of the mice in the eribulin group were tumor-free on day 14. A single low-dose eribulin was efficacious on a highly aggressive TNBC. The breast cancer PDOX model can be used to identify highly effective drugs for TNBC. Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.21873/anticanres.14218
  3. PMID: 32366392
  4. PII : 40/5/2481

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel